Results 171 to 180 of about 10,453,112 (207)

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

open access: yesCancer Science, EarlyView.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei   +9 more
wiley   +1 more source

Co-occurrence of selenium and toxic elements and health risk assessment in commercial selenium-enriched rice from China. [PDF]

open access: yesSci Rep
Xie Q   +11 more
europepmc   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

open access: yesCancer Science, EarlyView.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi   +12 more
wiley   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

open access: yesCancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

What Endocrinologists Should Know About Iodine: Population Deficiency, Individual Excess and Misinformation in the United Kingdom

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Iodine deficiency, once considered eliminated in the United Kingdom, has re‐emerged, particularly among women of reproductive age, in whom requirements are increased during pregnancy and lactation. The declining consumption of dairy and white fish, the emerging use of unfortified plant‐based milk alternatives, and the absence of a national ...
Peter N. Taylor   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy